|
|
NEWS ABOUT HAE
|
Surveys Reveal High Frequency of Prodromal Symptoms Prior to Acute Hereditary Angioedema Attacks
Patients with hereditary angioedema (HAE) experience prodromal or early warning symptoms before nearly three-quarters of their HAE attacks, according to survey findings presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
|
|
3/3/2010
|
Study Shows C1-Esterase Inhibitor Concentrate Rapidly Relieves Acute, Successive Attacks of Hereditary Angioedema at All Body Sites
C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks and successive attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2010 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
|
|
3/3/2010
|
|
B.E.N. ™ Offers Support System for HAE Patients, HCPs
|
|
1/27/2010
|
|
FDA Approves First Therapy for Treatment of Acute Abdominal or Facial HAE Attacks
|
|
10/12/2009
|
Survey Shows Rapid HAE Treatment Decreases Morbidity, Mortality
The importance of recognizing prodromal symptoms and treating acute attacks of hereditary angioedema (HAE) at the onset of these symptoms was highlighted in a survey presented today at the 2009 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
|
|
3/15/2009
|
C1-INH Concentrate Relieves Acute HAE Swelling
C1-esterase inhibitor (C1-INH) concentrate is an effective, well-tolerated therapy that rapidly relieves acute swelling attacks at any body location in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the 2009 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
|
|
3/15/2009
|
New C1-esterase Inhibitor Highly Effective in Hereditary Angioedema
Reuters Health covered CSL Behring's recent announcement that C1-esterase inhibitor (C1-INH) concentrate is a safe, effective therapy that rapidly relieves acute abdominal and facial swelling attacks in patients with hereditary angioedema (HAE), a rare and serious genetic disorder.
|
|
4/3/2008
|
C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
C1-esterase inhibitor (C1-INH) concentrate is a safe and effective therapy that rapidly relieves acute abdominal and facial swelling attacks in patients with hereditary angioedema (HAE), a rare and serious genetic disorder, according to data presented today at the American Academy of Allergy, Asthma & Immunology (AAAAI) 64th Annual Meeting. Results from the prospective, double-blind International Multi-center Prospective Angioedema C1-Inhibitor Trial (I.M.P.A.C.T. 1), the largest HAE study ever conducted, showed patients receiving C1-INH concentrate had a median time to symptom relief of 30 minutes, versus 90 minutes for patients receiving placebo. Additionally, interim results from I.M.P.A.C.T. 2, also presented at AAAAI, demonstrated for the first time C1-INH replacement therapy's effectiveness in rapidly relieving HAE attacks in peripheral body locations, such as the hands and feet.
|
|
3/25/2008
|
Novel Therapies May At Last Bring Relief for U.S. Hereditary Angioedema Patients
Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) ¿ a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening ¿ hope is on the horizon according to a team of experts presenting the latest research at the ACAAI Annual Meeting.
|
|
11/27/2007
|
Key Issues Dialogue: HAE & Primary Immune Disease
In February, three well-known members of the U.K. primary immunodeficiency community met with Eddie Owens of CSL Behring to discuss challenges and advances in diagnosis and treatment.
|
|
10/8/2007
|
|
|